Clinical trials
HNSCC clinical trials
Below are recruiting hnscc clinical trials, each written for real people, not researchers. We’re tracking 133 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06741982RecruitingPhase 1
Immune-targeted therapy and virus treatment before head and neck cancer surgery
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–70 - NCT06752798RecruitingPhase 2
Trilaciclib to protect bone marrow after head and neck cancer surgery and chemoradiation
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Changsha, HunanAges 18–70 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06794372RecruitingPhase 2
68Ga-FAPI-46 PET scan for head and neck cancer staging
This trial tests a new type of PET scan that uses a special tracer (68Ga-FAPI-46) to see if it can better show the extent of head and neck cancers before surgery. It may help doctors plan your treatment more accurately.
Lausanne, Canton of VaudAges 18 years+ - NCT06829095Recruiting
Nutrition counseling for esophageal and head and neck cancer patients
This trial tests whether personalized nutrition advice can improve the health of people with esophageal cancer or head and neck cancer who are getting chemoradiation. It may help you stay stronger and better manage treatment side effects.
New Taipei CityAges 18 years+ - NCT06876844RecruitingPhase 2
Surufatinib plus Envolizumab for advanced head and neck cancer
This study tests a new combination of two drugs (Surufatinib and Envolizumab) as a second treatment option for people with head and neck cancer that has returned or spread. It's for patients whose first treatment (usually chemo or immunotherapy) stopped working within 6 months.
ShanghaiAges 18–75 - NCT06935188RecruitingPhase 2
Dalpiciclib plus cetuximab for certain head and neck cancers
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT07027280Recruiting
Measuring Tumor Differences in Head and Neck Cancer
This study uses scans and tissue samples to look at differences within your tumor (called heterogeneity). It may help doctors understand your cancer better and choose the best treatment approach.
ChongqingAges 15–89 - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Denver, ColoradoAges 18 years+ - NCT07035249RecruitingPhase 1/Phase 2
DCSZ11 plus standard therapy for advanced solid tumors
This trial tests a new drug called DCSZ11 combined with usual chemotherapy and immunotherapy for people with advanced or metastatic solid tumors. It aims to see if adding DCSZ11 works better than standard treatments alone.
Chengdu, SichuanAges 18 years+ - NCT07063212RecruitingPhase 2
Sacituzumab govitecan plus cetuximab for head and neck cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT07081984RecruitingPhase 1
Testing TI-0093 for advanced HPV-16 positive cancers
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Tampa, FloridaAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07090317RecruitingPhase 2
Testing Two Immunotherapy Drugs for Advanced Head and Neck Cancer
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07131566Recruiting
Immune response in neck lymph nodes in head and neck cancer
This study looks at how the immune system in the lymph nodes of the neck responds to head and neck cancer. It will help researchers understand how the body fights these cancers, which could lead to better treatments.
Stockholm, Stockholm CountyAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT02128906RecruitingPhase 2
Radiation plus chemo choices for throat cancer, using a tumor marker
This trial compares two treatment combinations given with radiation for certain cancers of the throat. It also uses a lab test on the tumor (ERCC1) to help choose and study which treatment works better.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02678884Recruiting
PET-CT scan study for head and neck cancer before radiotherapy
This study uses PET-CT scans (a type of imaging that highlights active cancer cells) in people with a specific kind of head and neck cancer. The goal is to see how well the first scan identifies tumors that should be checked again with a second scan, to better guide care with radiotherapy.
Toronto, OntarioAges 18 years+
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hnscc?
- Yes. Clin2 currently lists 133 recruiting hnscc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hnscc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hnscc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.